Ladenburg Thalmann: Trius Therapeutics' Share Price Weak

In a research report published today by Ladenburg Thalmann, Trius Therapeutics Inc.'s

share price has been weak throughout the last few weeks. “We understand the lack of near term catalysts, for many, is a discouragement in today's market environment. However, we believe the current market cap of $185 million undervalues a well capitalized company with a differentiated product (tedizolid) and the potential to generate >$500 million in global revenues (according to our estimates) which already has positive Phase 3 data. In addition, we believe the potential for a tedizolid European corporate collaboration exists in 2012. Furthermore, TSRX has innovative platform technology (GyrB/ParE preclinical program) funded by an NIAID contract which could generate its first molecule for human testing in 2013,” Ladenburg Thalmann commented in the report. Ladenburg Thalmann maintains its Buy rating and $14 PT on Trius Therapeutics, which closed Friday at $4.81.